| abstract |
The present invention concerns cell lines and animal models of HER2-expressing tumors. In particular, the invention concerns cell lines and animal models of HER2-expressing tumors not responding or responding poorly to treatment with trastuzumab (HERCEPTIN®, Genentech, Inc.). The animal models and cell lines of the invention are useful for evaluating the efficacy of various therapeutic approaches for the treatment of such tumors. |